## UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 7, 2012

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## **Ligand Pharmaceuticals Inc.**

File No. 001-33093 - CF#28353

Ligand Pharmaceuticals Inc. submitted an application under Rule 24b-2

requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 4, 2012.

Based on representations by Ligand Pharmaceuticals Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through February 16, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kathleen Krebs Special Counsel